Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CAMP4 THERAPEUTICS CORPORATION (CAMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CAMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.91
1 Year Target Price $19.91
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.82M USD | Price to earnings Ratio - | 1Y Target Price 19.91 |
Price to earnings Ratio - | 1Y Target Price 19.91 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 1.30 - 12.30 | Updated Date 07/26/2025 |
52 Weeks Range 1.30 - 12.30 | Updated Date 07/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When After Market | Estimate -0.67 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 109743472 | Price to Sales(TTM) - |
Enterprise Value 109743472 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 315.31 | Enterprise Value to EBITDA - | Shares Outstanding 20161100 | Shares Floating 3915684 |
Shares Outstanding 20161100 | Shares Floating 3915684 | ||
Percent Insiders 35.4 | Percent Institutions 56.95 |
Upturn AI SWOT
CAMP4 THERAPEUTICS CORPORATION
Company Overview
History and Background
CAMP4 Therapeutics Corp. was founded in 2016 and is a clinical-stage biopharmaceutical company focused on discovering and developing RNA therapeutics to treat diseases.
Core Business Areas
- RNA Activating Therapeutics (RACTs): CAMP4 develops RNA activating therapeutics (RACTs), oligonucleotides designed to selectively upregulate gene expression. Their programs target various disease areas.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- CMP-3065: CMP-3065 is CAMP4's lead product candidate, designed to treat Spinal Muscular Atrophy (SMA) by increasing SMN1 protein expression. Currently in clinical trials. Competitors include Biogen (Spinraza), Novartis (Zolgensma), and Roche (Evrysdi).
Market Dynamics
Industry Overview
The RNA therapeutics market is experiencing rapid growth, driven by technological advancements and the potential to address previously untreatable diseases.
Positioning
CAMP4 is positioned as an innovator in RNA therapeutics, focusing on upregulation of gene expression. Their competitive advantage lies in their proprietary RACT platform.
Total Addressable Market (TAM)
The total addressable market for RNA therapeutics is estimated to be in the billions of dollars. CAMP4 is positioning itself to capture a significant share of this market with its RACT platform and pipeline of therapeutic candidates.
Upturn SWOT Analysis
Strengths
- Proprietary RACT platform
- Experienced leadership team
- Strong intellectual property portfolio
- Focus on novel therapeutic targets
Weaknesses
- Limited number of products in clinical trials
- High cash burn rate
- Reliance on third-party manufacturing
- Dependence on successful clinical trial outcomes
Opportunities
- Expansion of RACT platform to new therapeutic areas
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Advancements in RNA delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- RHHBY
- IONS
- MRNA
- ALNY
Competitive Landscape
CAMP4 competes in a crowded market with several larger pharmaceutical companies. Their success depends on the differentiation and efficacy of their RACT platform.
Growth Trajectory and Initiatives
Historical Growth: CAMP4's growth is characterized by the advancement of its RACT platform and pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships.
Recent Initiatives: Recent initiatives include advancing CMP-3065 into clinical trials and expanding the RACT platform.
Summary
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company with a novel RACT platform that presents both opportunities and risks. Its lead candidate, CMP-3065, holds promise but is subject to clinical trial success. Financial stability and strategic partnerships will be essential for navigating the competitive RNA therapeutics landscape. The company needs to focus on the successful execution of its clinical programs and the management of its cash burn rate. The company also needs to stand out among its competitors who have been in the market longer.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CAMP4 THERAPEUTICS CORPORATION
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2024-10-11 | CEO, President & Director Mr. Joshua Mandel-Brehm | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.camp4tx.com |
Full time employees 55 | Website https://www.camp4tx.com | ||
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.